Document is current
Any future updates will be listed below
-
Authors
Kasper, Bernd https://orcid.org/0000-0001-8425-8356
D’Ambrosio, Lorenzo
Davis, Elizabeth J.
Ingham, Matthew
Broto, Javier Martin
Trent, Jonathan C.
van Houdt, Winan J.
Van Tine, Brian A.
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
- License Information
-
More Information
Article History
Accepted: 26 July 2021
First Online: 11 March 2022
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL.
: BK declares personal fees from Ayala, Bayer, Blueprint, Boehringer Ingelheim, GSK, PharmaMar, Roche, and SpringWorks. EJD receives research funding from Bristol-Myers Squibb, Incyte, Five Prime, Karyopharm, Top Alliance BioSciences, Actuate, and Genentech and personal fees from Karyopharm and Deciphera. JCT serves as a consultant for Deciphera, Blueprint, Cogent Biosciences, Epizyme, C4 Therapeutics, and Daiichi-Sankyo. BAVT declares grants from Merck; grants and personal fees from Pfizer; grants from TRACON Pharmaceuticals; grants, personal fees, and others from GlaxoSmithKline; personal fees from Polaris Inc.; personal fees from Lilly; personal fees from Caris Life Sciences; personal fees from Novartis; personal fees from CytRX; personal fees from Plexxikon; personal fees from Epizyme; personal fees from Daiichi Sankyo; personal fees from Adaptimmune; personal fees from Immune Design; personal fees fromBayer; personal fees fromCytokinetics; and personal fees fromDeciphera; and has a patent issued for the use of ME1 as a biomarker and ACXT3102.
